Senti Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SNTI, updated each market day.
SNTI AI Sentiment
AI sees no strong directional signal for Senti Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Senti Biosciences, Inc. Common Stock
Senti Biosciences Inc is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Sector
Exchange
Market Cap
$31,455,941
Cap Tier
Employees
39
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
June 9, 2022
Website
SNTI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SNTI Volatility
Senti Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
